A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors

NCT05886075 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer
Bronchial Cancer
Non Small Cell Lung Cancer
Small Cell Lung Cancer
Sarcoma
Colorectal Cancer
Gastric Cancer
Liver Cancer
Breast Cancer
Pancreatic Cancer
Head and Neck Cancer
Ovarian Cancer

Interventions

DRUG: Recombinant oncolytic herpes simplex virus type 1 (R130)

Sponsor

Shanghai Yunying Medical Technology

Collaborators

[object Object]